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Abstract
Background: Since 1954, there have been in excess of 800 cases of rabies as a result of European
Bat Lyssaviruses types 1 and 2 (EBLV-1, EBLV-2) infection, mainly in Serotine and Myotis bats
respectively. These viruses have rarely been reported to infect humans and terrestrial mammals,
as the only exceptions are sheep in Denmark, a stone marten in Germany and a cat in France. The
purpose of this study was to investigate the susceptibility of foxes to EBLVs using silver foxes
(Vulpes vulpes) as a model.
Results: Our experimental studies have shown that the susceptibility of foxes to EBLVs is low by
the intramuscular (IM) route, however, animals were sensitive to intracranial (IC) inoculation.
Mortality was 100% for both EBLV-1 (~4.5 logs) and EBLV-2 (~3.0 logs) delivered by the IC route.
Virus dissemination and inflammatory infiltrate in the brain were demonstrated but virus specific
neutralising antibody (VNA) was limited (log(ED50) = 0.24–2.23 and 0.95–2.39 respectively for
specific EBLV-1 and EBLV-2). Foxes were also susceptible, at a low level, to peripheral (IM) infection
(~3.0 logs) with EBLV-1 but not EBLV-2. Three out of 21 (14.3%) foxes developed clinical signs
between 14 and 24 days post-EBLV-1 infection. None of the animals given EBLV-2 developed
clinical disease.
Conclusion: These data suggest that the chance of a EBLV spill-over from bat to fox is low, but
with a greater probability for EBLV-1 than for EBLV-2 and that foxes seem to be able to clear the
virus before it reaches the brain and cause a lethal infection.
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Background
Rabies is a viral zoonosis that causes progressive and
incurable encephalitis. Rabies infection is caused by neu-
rotropic RNA viruses belonging to the Rhabdoviridae fam-
ily, Lyssavirus genus. There are seven classified members of
Lyssavirus [1], the classical rabies virus (genotype 1) and
the rabies-related viruses (genotypes 2 to 7), with four
additional viruses identified more recently in bat species
from Europe and Asia: Aravan, Khujand, Irkut and West
Caucasian bat viruses [2,3]-these 4 isolates are proposed
as new genotypes.
Genotypes (gt) are associated in two immunopathologi-
cally and genetically distinct phylogroups [4]. Phylogroup
1 comprises five genotypes: Duvenhage virus (gt 4,
Africa), European Bat Lyssaviruses (EBLV-1 (gt 5, Europe),
EBLV-2 (gt 6, Europe), Australian Bat Lyssavirus (ABLV)
(gt 7, Australia) and the classical rabies virus (gt 1, RABV).
Classical rabies viruses circulate in Carnivora world-wide
and specifically in the Americas in Chiroptera. Phylo-
group 2 includes two African genotypes, Mokola virus (gt
3) and Lagos bat virus (gt 2) isolated from shrews, cats
and frugivorous and insectivorous bats. Members of clas-
sical rabies virus are found worldwide in Carnivora (both
domestic and wild) and in Chiroptera in the Americas),
ABLV in frugivorous and insectivorous bats (Australia)
while the following genotypes Duvenhage (Africa), EBLV-
1 and 2 (Europe) are isolated in insectivorous bats. It has
been shown [4], that genotypes of phylogroup 1 are path-
ogenic for mice when injected by intracranial and intra-
muscular routes, while Lyssaviruses from phylogroup 2
are less pathogenic by the intramuscular route.
In Europe, bats are important Lyssavirus reservoirs, with
more than 800 reported cases since 1954. Out of these
800 European rabid bats, 256 cases have been reported in
the Netherlands from 1984 to 2003 [5] and 187 in Ger-
many from 1954 to 2005 [6]. Bats infected with EBLV-1
and EBLV-2 have been reported in several European coun-
tries, from Russia to Spain, particularly in coastal regions
and more than 95% of the rabid bats are identified as Epte-
sicus serotinus. All infections in Eptesicus serotinus are due to
the two EBLV-1 subtypes (EBLV-1a and EBLV-1b) [7],
while the EBLV-2 subtypes are host-restricted to Myotis
species. Despite four fatal infections in man (and 3 non-
confirmed cases), European Bat Lyssaviruses have rarely
been reported to cross the species barrier: dead-end infec-
tions have been reported in Denmark in sheep [8,9] and
in a stone marten in Germany [10]. Antibodies have also
been reported from a cat in Denmark [11], suggesting evi-
dence of infection and more recently a cat from North-
western France was reported with rabies caused by
infection with EBLV-1 [12].
Since the late 1930's, in Europe, red foxes have been the
main reservoir and vector of classical rabies. Rabies virus
was shown to be highly pathogenic in the fox with an
incubation period varying from 11 days to 15 months
depending on the dose and on the route of inoculation
[13]. Comparative experimental studies on the patho-
genicity and on the transmission of rabies have been
undertaken using classical rabies virus and EBLVs on vari-
ous animal models: bats [14-16], mice [17-20], sheep and
fox [20-22], and ferrets [23]. The knowledge on the sus-
ceptibility of terrestrial, wild and domestic animals to
EBLV-1 and EBLV-2 remains limited.
In this study, we have undertaken experimental infections
of silver foxes (that belong to Vulpes vulpes species, i.e. the
same as red fox) by different routes and with different
viral doses. The sensitivity of silver foxes to rabies virus
isolated from naturally infected foxes has been experi-
mentally shown to be similar for red foxes (M. Artois et al.,
unpublished data).
The presence of the virus in different organs was assessed
using the fluorescent antibody test (FAT) and the rabies
tissue-culture infection test (RTCIT) [24-26] and reverse
transcriptase – polymerase chain reaction (RT-PCR) [27].
The presence of viral RNA on oral swabs was assessed by
RT-PCR. Specific neutralizing antibodies in serum sam-
ples were measured with classical and modified FAVNt.
Results
1st Clinical diseases in "infected" foxes and results of 
pathogenicity study
Experimental infection was conducted in several groups of
foxes (n = 5) according to virus strains, doses and routes
of infection. The outcome of infection for all infected
foxes in the five groups is presented in Table 1.
EBLV-1 and -2 IC pathogenicity experiment
- For the intracranial experiments using EBLV-1 and EBLV-
2, two trials were undertaken. In the first one, two groups
of two animals received 4.7 logs MIC LD50 of EBLV-1 and
3.2 logs of EBLV-2 respectively (group 2). In the second
trial, two animals were infected with 4.4 logs of EBLV-1
and 2.8 logs of EBLV-2 (group 5). (Additional file 1) One
negative control was included in that IC experiment.
All foxes in group 2, IC inoculated with either EBLV-1 or
EBLV-2, died between 8 and 10 days post-inoculation
(p.i.) and between 12 and 22 days p.i. respectively.
The animals showed clinical signs between 2 and 4 days
before euthanasia following EBLV-2 inoculation and
between 1 and 5 days following EBLV-1 inoculation. The
observed clinical signs were the following:
￿ EBLV-1 (fox 5FD-68AA receiving 4.7 logs MIC LD50),
dead 8 days p.i., dazed;BMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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￿ EBLV-1 (fox 5FD-5F3C, 4.7 logs), dead 10 days p.i., loss
of appetite, anorexia, hypersalivation;
￿ EBLV-2 (fox 601-15A3, 3.2 logs), dead 12 days p.i., loss
of appetite, anorexia, excitement, crisis;
￿ EBLV-2 (fox 601-E233, 3.2 logs), dead 22 days p.i.,
excitement, biting and very aggressive behaviour.
- In group 5, fox 5FE-5AEC inoculated with EBLV-1 (4.4
logs) died 8 days p.i following a phase of paralysis, fox
5FE-58DA inoculated with EBLV-2 (2.8 logs) died 282
days later, showing paralysis and alopecia.
Both antigen and infectious particles were detected by FAT
and by RTCIT in brain samples (cortex, hippocampus, cer-
ebellum and medulla oblongata) from all infected ani-
mals (5FD-68AA, 5FD-5F3C, 601-15A3 and 601-E233)
belonging to the group 2. Viral RNA was detected in the
same infected tissues for each animal. Salivary glands were
diagnosed rabies positive in foxes 601-E233, 5FE-58DA
and 5FD-5F3C inoculated respectively with 3.2 logs and
2.8 logs of EBLV-2 and 4.7 logs of EBLV-1.
IC EBLV-1 and 2 inoculated foxes (5FE-5AEC and 5FE-
58DA) belonging to the group 5 were diagnosed positive
by FAT (Additional file 1).
EBLV-1 and -2 IM pathogenicity experiment
- None of the 5 foxes intramuscularly inoculated with 3.5
logs MIC LD50  of EBLV-2 (group 1) died. All foxes
remained healthy during the 3-year observation period
with no signs indicative of rabies.
Following euthanasia of these five animals, no rabies virus
antigen, no infectious particles and no viral RNA were
detected in brain or salivary glands samples. None of the
five negative controls died during the experiment (except
fox numbered 126-DF42 that died of a non-rabid undeter-
mined cause 168 days p.i). All of the controls were lyssa-
virus negative using referenced diagnosis techniques.
- The doses of EBLV-1 intramuscularly inoculated to the
next group of foxes (group 3; n = 6) were distributed as
described in Additional file 1.
All six EBLV-1 inoculated foxes, except one (fox 634-8FE1
receiving a viral dose of 3.7 logs MIC LD50), survived the
challenge till 20 months p.i. and did not develop any clin-
ical signs indicative of rabies or suggestive of encephalitis.
The clinical rabies signs observed in fox 634-8FE1 that
died 14 days p.i. were: difficulty to swallow, balance prob-
lems, dazed appearance. The second fox inoculated with
the same dose (fox 633-6AD2) did not exhibit any clinical
signs and remained healthy during the 19-month of the
observation period. At necropsy of fox 634-8FE1, all spec-
imens of brain (hippocampus, medulla oblongata, thala-
mus, cortex and cerebellum) were shown to be positive by
FAT, RTCIT and RT-PCR. The sub maxillary salivary glands
(left and right) were tested negative by FAT. Fox 633-
6AD2 was diagnosed negative on brain by FAT, RTCIT and
RT-PCR.
- In the third IM experiment (group 4), 3 groups of five
animals were infected with serial dilutions of EBLV-1 (4.4,
3.7 and 3 logs MIC LD50) as described in Additional file 1.
One negative control was included in the assay.
All inoculated foxes, except fox 5FE-45F8 (receiving 3.7
logs of virus), 5FE-60DD (3.0 logs) and 5FD-ACB1 (3.0
logs) survived the challenge and did not develop clinical
signs of rabies or signs suggesting encephalitis, during the
13 months of observation. Fox 5FE-45F8 (3.7 logs), had
an infected wound on the back, it was euthanized on
humane grounds 61 days p.i. It was diagnosed negative by
FAT, RTCIT, and RT-PCR.
The clinical signs observed for the two animals 5FE-60DD
(3.0 logs) and 5FD-ACB1 (3.0 logs), moribund at 17 and
24 days p.i. were: loss of appetite, anorexia, "strange
behaviour evocative of classical rabies" and hypersaliva-
tion, prostration, excitement, tendency of biting the cage
respectively.
Comparative analysis of FAT and RT-PCR was undertaken
on different parts of brain and sub maxillary salivary
glands samples collected from foxes 5FE-60DD and 5FD-
ACB1 and showed respectively the presence of antigen in
medulla oblongata and thalamus, and cortex and thala-
mus. Viral RNA was shown in the same infected brain tis-
sues and in the following additional tissues:
hippocampus, cerebellum and cortex for fox 5FE-60DD
and in hippocampus, medulla oblongata, and cerebellum
for fox 5FD-ACB1. The sub maxillary salivary glands (left
and right) of the two dead animals were rabies negative by
FAT and by RT-PCR.
Virus was not isolated from control foxes 126-C920 and
601-F206 that were located in adjacent cages to chal-
lenged animals. Following necropsy of these control ani-
mals, viral RNA and rabies virus antigen was not detected
from brain samples.
Detection of viral RNA or infectious virus on oral swabs
The confidence of negative PCR results was established by
checking for each test the amplification of internal con-
trol, 18S rRNA.
All oral swabs taken all over the experiments from foxes
inoculated intramuscularly and intracranially with undi-BMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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luted stock or serially diluted EBLV-1 and EBLV-2 viruses
were negative both by RTCIT and by RT-PCR. The fox
numbered 5FD68AA, inoculated intracranially with
EBLV-1 (EBLV-1 IC group) died 8 days after infection, nei-
ther viral RNA nor infectious virus were detected in the
oral swab taken one day before the mortality (D7).
Neither viral RNA nor infectious particles were detected
on oral swabs taken from "uninoculated" animals during
all experiments.
Rabies virus neutralizing antibodies
The measurement of seroneutralising antibodies has been
commonly used for many years to assess the level of pro-
tective immunity against rabies in animals. Serological
monitoring is used as VNA is the principal modality of
protection following rabies infection, which can be corre-
lated with the dose.
In seroneutralisation tests, the dilution of the serum that
neutralises 50% of the challenge virus is the efficient dilu-
tion 50% (ED50). The comparison of this ED50 with the
one of a reference serum whose titre in IU/ml is estab-
lished gives the titre of the tested serum. In all the FAVN
tests published here, the reference serum used was the OIE
international serum of dog origin.
Figure 1 shows the dynamics of rabies virus neutralizing
antibodies of all experimented foxes. Each figure expresses
FAVNt results with the neutralising response obtained
against either CVS-11 or EBLV-1.
For these serological tests, the log (ED50) value of 1.55
corresponds to the specific EBLV-1 titre of 1 UI/ml meas-
ured with the OIE dog reference serum that is calibrated
against CVS-11. As there are no specific reference serum
for EBLVs with a recognized titre (in IU/ml), we have cho-
sen to express the serological results as the log(ED50) that
corresponds to the neutralization of 50% of the challenge
virus.
Several studies on the sensitivity of FAVN test have shown
that the threshold of positivity of 0.24 UI/ml could be
adopted [28,29]. Based on these previous studies, we
assume for this serological study, that animals serocon-
verted above the value of 1.00 log for ED50 in both EBLV-
1 mFAVN and CVS-11 FAVNt.
EBLV-1 serology
At day 0, all experimented foxes were negative for rabies
virus antibody by using both EBLV-1 mFAVNt and CVS-11
FAVNt.
In group 1 (Additional file 1, figure 1A1), all the 5 intra-
muscularly inoculated animals developed EBLV-2 anti-
bodies. Thirty five days p.i., animal 13C-A15A showed a
log(ED50) = 1.79. The four remaining animals ranged
between 0.24 and 0.36 IU/ml. Four days later (i.e. 39 days
p.i.), 4 out of the five inoculated animals showed a rabies
EBLV antibody peak (geometric mean = 1.00) with a max-
imum of 1.67. At the end of the trial (1097 days p.i.) one
surviving animal presented a high log(ED50) of 1.19 while
the 4 others ranged between 0.24 and 0.48.
In group 3 (Additional file 1, figure 1B1), different doses
of EBLV-1 were used. Four animals out of the five serocon-
verted 12 days post infection with log(ED50)> 1.00, the
mean of log(ED50) was 1.85. This value peaked at 2.20 on
day 26 p.i. and remained stable up to 81 days p.i. (mean
= 1.65). At the end of trial (651 days p.i.), the mean
log(ED50) was 1.25. Two of the 4 surviving animals dem-
onstrated a log(ED50) still positive: 2.15 and 1.91.
In group 4 (Additional file 1, figure 1C1), 14 out of the fif-
teen animals IM infected with EBLV-1 developed rabies
antibody between 11 and 24 days post infection with a
mean log(ED50) of 0.96 and 1.58 respectively. This value
decreased down to 0.44 at the end of trial. One animal
(5FD-8E03), receiving 3.7 log of MIC LD50 of infectious
virus did not develop antibodies after inoculation, all
along the experiment, the log(ED50) was under 0.24.
Considering that the cut off value for log(ED50) is 1.00, 13
animals seroconverted (log(ED50) ranging between 1.08
and 2.63) between 11 and 48 days p.i. The 2 foxes that
died after inoculation (5FE-60DD and 5FD-ACB1) devel-
oped detectable EBLV-1 antibodies before succumbing:
log(ED50) = 0.96 and 1.91 respectively 14 and 17 days p.i.
At the end of the experiment, the mean log(ED50) was
1.01 in surviving animals.
Five days after intracranial inoculation with pure EBLV-1
the log(ED50) of fox 5FE-5AEC, peaked at 1.08 and then
decreased to 0.72 at day 7. The animal was euthanised on
day 8 p.i. The other animal intracranially inoculated with
EBLV-2 (5FE-58DA) did not develop detectable antibody
during the entire experiment, the log(ED50) varied
between 0.24 and 0.36 between inoculation and 136 days
p.i. The animal was euthanased 282 days p.i. with symp-
toms, without serological analysis of blood samples by
FAVNt.
All negative control animals belonging to the five groups
remained seronegative with log(ED50)<0.24 throughout
the experiments.
EBLV-2 serology
Foxes inoculated via the IC route did not seroconvert prior
to clinical disease during the 22 days of observation
(log(ED50) = 0.95).BMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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Kinetics of EBLV-1 and CVS-11 neutralizing activity for foxes intramuscularly infected with EBLV-1 and EBLV-2 Figure 1
Kinetics of EBLV-1 and CVS-11 neutralizing activity for foxes intramuscularly infected with EBLV-1 and EBLV-
2. Neutralising activity is expressed by log(ED50): dilution giving a 50% neutralization of rabies virus (CVS-11/EBLV-1). Figure 
1A: mean of VNA response of 5 foxes intramuscularly inoculated with 103.5 MIC LD50 of EBLV-2 (group 1). The 5 negative con-
trols did not develop any rabies neutralising activity during the entire experiment (log(ED50) < 0.24, data not shown). Figure 
1B: mean of VNA response obtained in the second trial with intramuscular inoculation of different doses of EBLV-1 (group 3). 
One fox received 104,7 MIC LD50, one 104,4 and 2 groups of 2 received respectively 103.7 and 102.7. One negative control did 
not develop any rabies neutralising activity all over the experiment (log (ED50)< 0.24, data not shown). Figure 1C: VNA 
response obtained from the fourth IM trial with EBLV-1 (group 4). 3 groups of 5 animals received respectively the final dose of 
4.4, 3.7 and 3 logs MIC LD50. One negative control fox did not develop rabies neutralising activity all over the entire experi-
ment (log(ED50) < 0.24, data not shown). Remark: All neutralising activities are expressed with log(ED50) due to the absence of 
an available specific reference serum of known neutralizing titre against EBLVs.
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The log(ED50) of EBLV-2 specific antibodies of animals
inoculated via the IM route generally fluctuated between
1.55 and 2.39, i.e. above the positive threshold (1.43)
between days 30 and 330 Of the 5 animals, three had sub-
stantially higher antibody levels than the other two.
There were substantial differences between the specific
serological responses of the EBLV-2 inoculated animals
depending on whether the sera were tested against a
homologous genotype (i.e. EBLV-2) or a heterologous one
(EBLV-1 or CVS).
CVS serology
In group 1 (Additional file 1, figure 1A2), three animals
out of the five animals infected with 3.5 log MIC LD50 of
EBLV-2, seroconverted, log(ED50)>1.00 between 28 (13C-
A15A: 1.08) and 49 days p.i. (1E2-CB6E: 1.43 and 1E2-
D586: 1.67, which is the maximal value observed in this
study). The log(ED50) of two other animals (13C-F633,
1DF-7D9E) was 0.24 and 0.84. At the end of the trial, all
surviving animals (n = 5) presented a log(ED50) between
0.24 and 0.48.
Five foxes intramuscularly inoculated with EBLV-1 (group
3, Additional file 1, figure 1B2) seroconverted with
log(ED50) between 1.08 and 2.03, 12–29 days p.i. The
mean value peaked at 18 days p.i. (1.24) and decreased
down to 0.65 21 months p.i.
In the final IM EBLV-1 experiment (group 4, Additional
file 1, figure 1C2), only 6 animals out of the 15 infected
seroconverted above 1.00 between 11 and 39 days post
inoculation, with a mean log(ED50) varying between 0.38
and 0.47. The mean log(ED50) for FAVNt conducted with
CVS-11 increased from 0.29 to 0.62 (14-days p.i), then
decreased to 0.44 at the end of the trial.
Histopathology
EBLV infected animals were euthanased at a time of
advanced disease after which necropsy took place. Both
neural and extra-neural tissues were collected for pathol-
ogy studies. It was observed that brain tissue from IC inoc-
ulated foxes demonstrated greater meningoencephalitis
or gliosis in the form of generalised and focal cellular
infiltrate including peri-vascular cuffing in EBLV-2
infected foxes than EBLV-1 infected animals (Figure 2,
panels E, F, H and I) similar to that seen in EBLV-2
infected experimental mice [30]. The distribution and
intensity of lyssavirus antigen detection varied between
viruses and inoculation route. There was substantially
more immunostaining on brain tissue from EBLV-1
infected animals than that from EBLV-2 infected animals
following IC inoculation. Regional differences were most
prominent in the hippocampus and cerebellum. Compar-
ison of results between IC and IM routes was only possible
in the case of EBLV-1 as no animals peripherally inocu-
lated with EBLV-2 succumbed to disease. In the case of
EBLV-1 both antigen detection and inflammatory infil-
trate varied in regions of the brain. The most obvious dif-
ferences included the rarity of infected neurons in the
hippocampus in IM inoculated animals and enhanced
inflammatory infiltrate in the thalamus and medulla.
Cervical spinal cord sections were positive in both IC
inoculated EBLV-1 and EBLV-2 infected animals with dis-
tinct signal in many (40–50%) motor neuron cell bodies.
Thoracic and cervical spinal sections were negative as con-
firmed by PCR and virus re-isolation (RTCIT). Isolated
neurons in the brachial plexi were also positive but this
could not be confirmed by other methods. Other extra-
neural tissues contained a small number of non-specifi-
cally stained cells.
Discussion
Red foxes are the principal reservoir and vector of classical
rabies virus (genotype 1) in Western Europe [31]. Thanks
to the campaigns of oral vaccination of foxes, France and
other Western European countries have been rabies free
for many years [32]. This study was undertaken to assess
the risk of spillover of a bat lyssavirus strain from a bat to
a fox and causing rabies infection with EBLV-1 and EBLV-
2, and to investigate whether or not foxes can transmit
EBLVs. These experiments were conducted with high
doses of virus using two different routes of infection:
intramuscular and intracranial.
In our study, we have shown that all foxes infected exper-
imentally intracranially with undiluted stock or diluted
batches of EBLV-1 and 2 exhibited clinical signs of rabies
and succumbed between 8 and 282 days post infection.
All clinically ill foxes developed neutralising antibodies
and contained viral antigen, infectious particles and viral
RNA in the brain. Salivary glands were positive in three
out of six animals, but none of the oral swabs collected
from these animals were positive for viral RNA or infec-
tious particles.
The two successive intramuscular trials undertaken with
EBLV-1 (groups 3 and 4) did not give reproducible results,
and surprisingly, some foxes challenged with the minimal
doses of EBLV-1 succumbed and presented neurological
clinical signs indicative of rabies. Surprisingly, in both tri-
als, none of the foxes infected with undiluted stock suc-
cumbed, and all but two, developed a high neutralising
antibody response suggesting an abortive peripheral
infection. Similarly to intracranial experiments, neither
viral RNA nor infectious particles were detected in any of
the saliva obtained with oral swabs collected regularly
from all infected animals and kept dry on ice until analy-
sis.BMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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In our study, we have shown the influence of the strain of
challenge virus used in FAVN assays (homologous vs. het-
erologous). Similar observations have been previously
reported by Moore et al [33]. FAVNt assays using homol-
ogous virus (EBLV-1) reported higher neutralising titres
for all foxes infected intramuscularly with EBLV-1 than
when the assay was conducted against CVS-11. This differ-
ential neutralising response has also been observed from
a qualitative point of view. With the EBLV-1 modified
FAVNt, 17 of the 21 experimented animals seroconverted
while only 6 seroconverted with FAVNt conducted against
CVS-11.
Rabies pathogenesis has been assessed by several groups
by using different variants of Lyssavirus including the clas-
sical genotype 1 isolated from infected American bats,
dogs or foxes [34-36], and EBLV-1 and EBLV-2 on ferrets,
sheep, foxes, cats and mice [17,20-23]. More recently,
experimental studies in bats using EBLV-1 and EBLV-2
have shown that bats are likely to transmit the virus fol-
lowing a shallow bite to peripheral tissue [15,16].
Infection on mice with EBLV-1 in our experiments
involved agitation, hyperactivity and aggressiveness
before death (data not shown). Clinical signs observed in
mice after infection with EBLV-2 were different from the
ones following EBLV-1 infection: prostration and paraly-
sis before death are frequent (VLA, unpublished data).
The same variable clinical signs have also been observed
in foxes after infection with rabies viruses: experimentally
infected foxes first exhibit loss of appetite, hyperactivity,
tremor, hypersensitivity, and sudden aggressiveness, con-
vulsions and paralysis are common late signs [37,38]. In
our study, we observed that the clinical phase is short and
varies between 2 to 6 days. Similar results were shown by
some rabies pathologists and reviewed by Wandeler in
2004 [38], the clinical phase lasted one to seventeen days
[38,39].
In this study, foxes have been infected intracranially (i.e.,
non classical route different from previous trial with fox
and classical virus strains) and only six animals have been
inoculated. The two facts make the comparison of
observed clinical signs between EBLVs and genotype 1
virus inconclusive. The only reliable observations under-
taken on these foxes are the following: death occurs
within one week post inoculation and usual clinical signs
of rabies have been observed.
Red foxes have been shown to be highly susceptible to
classical rabies by the intramuscular route, for example,
the IM LD50 of a street rabies virus isolated in North Amer-
ica intramuscularly was less than 5 MIC LD50 [40]. In the
same way, Blancou et al. [39] showed that the intramus-
cular route is 12.6 × 105 to 15.85 × 105 times more effi-
cient to infect red foxes than the oral route. The dose of
virus, the route of inoculation and entry into the central
nervous system are of the utmost importance. It has been
suggested that both virus and host factors including strain,
route of inoculation, distance of inoculation site from the
brain and the immunologic status of the host, influence
the incubation periods, and whether the resulting infec-
tion is abortive or fatal [41].
In our study, we have shown that fatal clinical diseases can
be induced by intracranial route, while the intramuscular
route and a high dose of EBLV result in a non-fatal disease,
accompanied by a serological neutralising response. Sim-
ilar to our study, it has been shown by Blancou et al. [42]
that foxes were susceptible to low doses of canine rabies
virus from North Africa, and resisted the inoculation of a
high dose and became immune, reflecting a possible
Immunohistochemistry using the Swiss anti-rabies mono- clonal antibody to detect Lyssavirus antigen in infected fox  brain tissue Figure 2
Immunohistochemistry using the Swiss anti-rabies 
monoclonal antibody to detect Lyssavirus antigen in 
infected fox brain tissue. Histopathology legend: Panels 
A-C* were from an EBLV-1 infected animal inoculated via the 
IC route. Panels D-F were from an EBLV-2 infected animal 
inoculated via the IC route. Panels G-I were from an EBLC-1 
infected animal inoculated via the IM route. Panels A, D and 
G were from the hippocampus and panels B, E and H were 
from the thalmic region. Panel C was from the cortex, panel 
F from the cerebellum and panel I was from the medulla. 
Arrows on panels F indicate antigen accumulation reminis-
cent of Negri bodies, and arrows on panels E and I indicate 
perivascular, inflammatory infiltrate is also evident in panels 
E, F, H and I. Arrows on panel G highlight rare positive cells 
in the hippocampus of an IM inoculated animal. *these sec-
tions have a higher 'coffee wash' background as the carcass 
was frozen prior to post-mortem.BMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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abortive peripheral infection or a failure in virus replica-
tion.
Spill over of rabies virus (genotype 1) has been reported
to occur from bats to red foxes in Newfoundland, Canada
[43] and from bats to skunks in Arizona, USA [44]. These
observations suggest that North American bat strains of
rabies virus more readily spill over and adapt to a new
host when compared with EBLVs. We speculate that these
observations suggest that 'Old World' bat strains of rabies
virus have evolved over thousands of years and are fully-
adapted to their chiropteran host. In contrast, we hypoth-
esise that 'New World' bat strains of rabies virus are in evo-
lutionary terms 'younger' viruses, are less adapted to their
chiropteran host and are therefore more prone to spill
over in search of a new mammalian host.
Because of the narrow co-adaptation between a rabies
strain and its usual normal host, spill overs into other spe-
cies have a very low probability in relation to establishing
a new rabies cycle. It means that specific virus variants
within a single genotype (fox – dog variants in genotype
1) tend to be maintained in their specific hosts without
mixing. As for Carnivora, the compartmentalisation of bat
rabies seems to be the epidemiological rule, although
spill-over infection to other mammals has been docu-
mented [45].
Natural transmission of EBLV-1 to terrestrial animals has
been previously reported in Danish sheep [8,9] and in a
stone marten in Germany [10], the first case of transmis-
sion in terrestrial wildlife. Ferrets have been reported by
Vos et al. [23] as being susceptible to infection with a high
dose of EBLV-1 (between 104 to 106 FFU), resulting in an
incubation period of between 7 and 15 days. These ani-
mals are dead-end hosts and are unable to transmit the
infectious virus to a new host. Similarly to our results, all
ferrets that became clinically ill were positive by FAT in
brain, all oral swabs were negative and viral RNA could
only be detected in salivary glands of infected animals
[23].
It has rarely been reported that infection of mammals
with EBLV has resulted in fatal disease [22]. Soria Balt-
hazar et al. [46] infected sheep with an EBLV-1 virus iso-
lated from a rabid bat (Eptesicus serotinus) in Denmark in
1985 (originally identified as "Duvenhage like" virus),
with doses ranging between 105.6 and 104.6 MIC LD50.
Only one animal infected with the highest dose suc-
cumbed to disease 30 days post inoculation, the incuba-
tion period lasted 8 days. No antigen was detected in the
brain while infectious particles were detected by mouse
inoculation test. Additionally, it has been shown in the
same study, that 3 out of 5 foxes intramuscularly inocu-
lated into the masseter with different doses of "Duven-
hage like" virus, died between 11 and 20 days post
infection [46]. Rabies diagnosis (FAT, Negri bodies and
mouse inoculation test) undertaken on the brains of these
3 animals showed the presence of rabies antigen in two
and infectious particles have been detected in one.
All of these experiments, including our results, strongly
suggest that the outcome of disease after exposure to
EBLVs may be dependent on the host species, the inocula-
tion site and the type of infecting virus.
Most natural rabies cases result from the bite of a rabid
animal [46], although infection through aerosols under
experimental conditions in mice has been reported [19].
The other routes of infection are rare. Few studies have
been undertaken to monitor the viral shedding of natu-
rally or experimentally infected animals. Bats naturally or
experimentally infected with genotype 1 Lyssavirus have
been shown to harbour virus in the nasal mucosa [47] and
in the saliva (T. brasiliensis, [48]) respectively, leading to
the supposition that a transmission between bats living in
the same colony is possible. Recently Hughes et al. [49]
reported the presence of viral RNA in oral swabs of exper-
imented bats infected with Khujand and Irkut new Lyssa-
viruses, between 0 and 2 days before the onset of illness.
In 2006, the presence of viral RNA has been detected by
molecular tools on an oral swab collected from a com-
mon serotine naturally infected with EBLV-1 three days
before death; no infectious virus was detected. Our exper-
iments have not detected viral RNA or virus infectious par-
ticles in any of the oral swabs collected throughout the
experiments. As observed in other infection models, shed-
ding of virus may be intermittent and can explain the
absence of detection of viral RNA in oral swabs. Compar-
ative studies should be undertaken in order to further
ameliorate our understanding of rabies virus excretion in
saliva and salivary gland infection.
The diseased brain tissue was characterised by diffuse
meningioencephalitis with gliosis and perivascular cuff-
ing as observed in EBLV-1 infected cats and dogs [17] and
viral antigen is seen in neurons throughout the various
regions of the brain. There was a suggestion of antigen dis-
tribution differences in the cerebellum and hippocampus;
the signal appeared less intense and more focal in EBLV-2
compared to that in EBLV-1 infected tissue. In general the
number of infected cells and intensity of staining was
greater for EBLV-1 than EBLV-2, inclusion bodies similar
but less distinct than RABV Negri bodies were observed in
EBLV-2 infected cells but rarely in EBLV-1 infected tissue,
and inflammation was more prevalent in EBLV-2 than
EBLV-1. Inflammation of the brain in the form of gliosis
and perivascular cuffing were also observed in those foxes
that succumb to clinical disease; EBLV-1 IC and IM and
EBLV-2 IC inoculations.BMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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Similar observations recently conducted by Brookes et al.
[22] on IC and IM sheep experiments with EBLV-1 and-2,
showed that as the previous study conducted on ferrets
[23], EBLVs show a limited capacity to induce lethal dis-
ease when inoculated at a peripheral site (IM route).
The pathogenicity of EBLV-1 for foxes appears to be low
using the intramuscular route, which closely mimics the
classical natural transmission route of rabies virus to new
hosts. Furthermore, the absence of detection of infectious
particles or of viral RNA in saliva throughout the intracra-
nial and intramuscular experiments undertaken in our
study suggests that foxes may not be able to transmit
EBLV-1 as virus was not detected in the saliva of clinically
infected animals. The chance of EBLV spill over from bat
to fox is low, there is a minimal chance of contact between
insectivorous bats and foxes which seem to be dead-end
hosts for EBLVs viruses.
Conclusion
The susceptibility of foxes to experimental infection with
EBLVs appears to be very low and thus the virus represents
a low risk to red foxes in the population. This does not,
however, negate the fact that red foxes are the main host
and vector of classical rabies in Europe. Further studies,
including the use of different EBLV isolates and doses, dif-
ferent routes and sites of infection and the use of other
potential host species as experimental models are
required in order to ameliorate our understanding of
pathogen adaptation and of the host response, which can
result in an abortive infection, survival with clinical
sequelae or lethal infection. Further in vitro studies on the
EBLV-1 neurotropism and similar fox experiments with
the subcutaneous route to mimic superficial exposure
should be undertaken to assess the risk of EBLV spillover.
Methods
Animals
The captive bred silver foxes used in the study were pur-
chased from the breeding centre of the Norvegian Fur
Breeder's Association (Oekern, 0509, Oslo, Norway).
These animals belong to the same zoological species as
the red fox, Vulpes vulpes. All animals were individually
identified with microchips. They were kept for observa-
tion in individual cages. They were fed daily with com-
mercial food for dogs (PR27 Royal Canin, France) and
watered ad libitum. Animals were clinically observed once
or more daily and the general behaviour of each animal
was recorded by two trained personnel.
Viruses
EBLV-1b and EBLV-2b strains were passaged 3 times
intracranially in mice from the original bat brain. A 10%
brain suspension was prepared in DMEM and clarified by
centrifugation at 1500 g at 4°C for 30 minutes. The viral
stocks were stored in liquid nitrogen in 0.75 ml aliquots
having a viral titre of 5.4 log MIC LD50/ml for EBLV-1 and
4.2 log MIC LD50/ml for EBLV-2 stock. These stocks con-
stituted the challenge batch used for all experimental
inoculations. Back titration in mice was undertaken after
each experiment to confirm the inoculated dose.
EBLV-1 virus was isolated from the brain of a naturally
rabid serotine bat (Eptesicus serotinus) found in Lurcy Levis
in the Centre of France in 2002 (animal registered under
no:123008 in AFSSA Nancy, France). The challenge strain
of EBLV-2 was prepared from an infected Myotis daubento-
nii from Lancashire in United Kingdom [50] (animal reg-
istered under no:RV1332, VLA, United Kingdom).
Experimental infections
Three studies were conducted according to instructions
related to animal experimentation provided by the French
Ethical Committee using EBLV-1 and EBLV-2 viruses in 40
animals. Both intramuscular and the intracranial routes
were used. Additional file 1 summarises the experimental
details (identification of foxes, route of inoculation, vol-
ume injected, dose and type of virus inoculated, viral dose
expressed in LD50/mouse).
The intramuscular injection was administered deep in the
left temporal muscle with a volume of 1 ml of viral sus-
pension on vigil animals. The intracranial injection was
undertaken with a volume of 0.5 ml on anaesthetized
foxes (0.85 mg/kg medetomidine plus 100 mg/kg keta-
mine IM). The frontal bone was then trephined 1 cm
behind the insertion of temporalis muscle and 2 cm left of
the sagital plan. The injection was given slowly with a 0.6
mm in diameter needle introduced 20 mm in the hole.
After the skin suture, the recovery product (atipamezole
4.28 mg/kg, IM) was injected and a preventive antibiotic
treatment was conducted (amoxicillin, 15 mg/kg SC) for
5 days. Using this procedure, the injection site was sup-
posed to be roughly identical to the one used in mice, i.e.
in the first third of the cortex.
Clinical observations and sampling
Before the inoculation of foxes, serum and saliva samples
were collected from all 40 animals and stored at 4°C until
examined for neutralizing antibodies and rabies virus
using the cell culture test and by PCR as described below.
The first group of animals included 5 EBLV-2 inoculated
(IM) animals and 5 negative controls, serum and saliva
samples were regularly collected once a week during 2
months, then on a monthly base over 2 years, i.e. on days
0, 7, 28, 32, 35, 38, 42, 46, 49, 53, 56, 63, 77, 137, 189,
230, 250, 320, 351, 383, 418, 446, 474, 518, 546, 565,
600, 676 & 1097. The second group included 4 animals
inoculated intracranially with EBLV-2 and one control,BMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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samples of serum and saliva were collected 7 days post-
infection. All animals in group 3 (6 EBLV-1 inoculated
intramuscularly, 1 negative control) and group 5 (1 EBLV-
1 intracranially inoculated and 1 EBLV-2 intracranially
inoculated), had both serum and saliva samples collected
on days 0, 5, 7, 12, 14, 18, 22, 26, 29, 36, 41, 43, 47, 50,
57, 81, 136, 181, 314, 404, 503 and 651. The last group of
animals (15 EBLV-1 foxes intramuscularly inoculated
with varying inoculation doses and 5 uninoculated con-
trols) samples were collected on the following days: 0, 3,
6, 11, 14, 18, 24, 28, 32, 39, 48, 110, 200 & 454.
Rabies diagnosis, Molecular biology applied to rabies virus, 
serology and related procedures
After humane euthanasia of animals (either those having
demonstrated clinical signs, humane end-points or at the
end of the experiment) with intravenous T61 (Intervet,
France), samples were collected from the brain (left and
right areas of the hippocampus, portions of medulla
oblongata, portions of thalamus, portions of cortex and
cerebellum) and from sub-maxillary salivary glands.
These samples were then analysed to detect for the pres-
ence of antigen (FAT), infectious virus (RTCIT) and viral
RNA (VPCR), as described below.
Fluorescent antibody test: FAT
The FAT was undertaken as previously described [24].
Briefly, impression smears from the eight different areas
of the brain and salivary glands were undertaken, air-
dried, fixed in cold acetone at -20°C for 30 minutes and
stained with a polyclonal fluorescein isothiocyanate
labelled rabbit anti-rabies virus nucleocapsid immu-
noglobulin (BIORAD, France). The slides were then read
under a fluorescent microscope by two trained laboratory
personnel.
Histopathology
Tissue samples from all animals were fixed in 4% phos-
phate-buffered formaldehyde and processed for paraffin-
embedding. Paraffin-wax sections (3 μm) were dewaxed
and stained with haematoxylin and eosin. To analyze dis-
tribution of EBLV antigens within the brain, sections were
mounted on SuperFrost® plus microscope slides, dewaxed
and rehydrated as described by Brookes et al. [22]. The
sections were incubated with a mouse monoclonal anti-
body against the lyssaviral nucleoprotein antigen (Swiss
MAB-HAM, kindly provided by the Swiss Rabies Centre)
at a dilution of 1:800 in Tris-buffered-saline (TBS, 0.1 M
Tris-base, 0.9% NaCl, pH 7.6). A biotinylated goat anti-
mouse IgG1 (Vector, Burlingame, CA) was used as linker-
antibody for the avidin-biotin-complex (ABC-) method. A
nonspecific primary antibody (source of isotype control)
and mock infected control mouse tissue acted as negative
controls and were analysed in parallel. By means of the
ABC-method and an immunoperoxidase kit (Vectastain
Elite ABC Kit, Vector), a brown-red signal was obtained
from the substrate 3-amino-9-ethylcarbazole (DAKO AEC
substrate-chromogen system; Dako, Carpinteria, CA,
USA). The sections were counterstained with Mayer's hae-
matoxylin, and sealed with aqueous medium (Aquatex;
Merck, Darmstadt, Germany).
Cell culture inoculation test: RTCIT
The test was undertaken using a modified procedure as
described by Barrat et al. [26] in eight chamber labtek
slides. Ten percent (w/v) tissue suspensions were prepared
using DMEM containing antibiotics and 50% NBCS and
centrifuged at 1500 g for 10 minutes. A volume of 50 μL
of supernatant from each sample (brain, salivary glands)
was then added to individual wells containing 0.4 × 105
neuroblastoma cells in 400 μl. Following incubation at
35°C (with 5% CO2) for 48 hours, the medium was
changed 1 day later, on day 2 cell culture medium was dis-
carded and the slides were fixed in cold acetone, stained
and examined as described for the FAT.
In the same manner, the cell culture test was undertaken
on the pre-weighted oral swabs which had been kept dry
on ice till the end of sampling. The swabs were 1:10 (m:v)
diluted with medium culture supplemented with antibi-
otics, centrifuged at 4000 g for 30 minutes and the swabs
were discarded. The eluate was stored at +4°C after cen-
trifugation then tested by cell culture test and by RT-PCR
before freezing at -80°C. Positive (CVS-27 and EBLV-1)
and negative (cell culture medium) controls were incor-
porated in each test.
RNA extraction and RT-PCR
Viral RNA was extracted from 150 μL of either 10% tissue
suspensions supernatant (different areas of brain and sal-
ivary glands) or from swab medium using Qiagen Viral
RNA mini kit according to the manufacturer's instruc-
tions. First and second round polymerase chain reactions
were carried out as described by Heaton et al. [51] Host
RNA control (18S rRNA) was amplified for each sample
with RT-PCR according to the technique previously
described by Smith et al. [52].
Controls
To avoid false-positive PCR results, the usual precautions
for PCR were strictly followed in the laboratory [53].
Amplification of 18S rRNA was undertaken for each sam-
ple to control the integrity of RNA and validate each neg-
ative result of RT-PCR. All samples were then analysed
twice: once for host rRNA (18S rRNA,) and the second
with lyssavirus universal primers [51].
Serology
The detection of EBLV-1, EBLV-2 and CVS-11 specific neu-
tralising antibodies in the serum samples collected fromBMC Veterinary Research 2009, 5:19 http://www.biomedcentral.com/1746-6148/5/19
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foxes was carried out by using the modified and standard
fluorescent antibody virus neutralization test (mFAVN,
FAVNt) [54,55]. EBLV-2 mFAVN was undertaken at the
VLA laboratory, FAVNt with CVS-11 and EBLV-1 mFAVN
were undertaken at the AFSSA laboratory.
Briefly, duplicate or quadruplicate serum samples, with a
volume of 50 μl, were diluted, added to each well, incu-
bated at 37°C for 1 hour with around 100 TCID50 of spe-
cific virus: CVS-11, acting as positive control and EBLV-1
or EBLV-2. A volume of 50 μl of BHK-21 cells suspension
was added in each well and left for two days at 37°C,
before staining with fluorescein-isothiocyanate anti-
rabies monoclonal antibody (Centocor INC, Malvern,
Pennsylvania, USA). Controls included uninfected BHK-
21 cells, OIE positive serum, negative serum from dog and
titration of specific virus (CVS-11, EBLV-1). And rabbit
anti-EBLV-1 and EBLV-2 for performing EBLV-2 modified
FAVNt.
An additional positive control for FAVNt was carried out
by using CVS-11. VNAs were expressed in log ED50 giving
a 50% neutralization of rabies virus (around 100 TCID50
of CVS-11, EBLV-1 and EBLV-2) the reference material for
EBLV-1 neutralizing antibodies detection being not avail-
able for the experiments.
The threshold of positivity was established to 1.19 log
ED50 for CVS-11, 1.25 log ED50 for EBLV-1 and 1.43 for
EBLV-2.
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